Healthcare platform Sesame announced a new weight loss program offering compounded versions of Novo Nordisk A/S's (NYSE:NVO) blockbuster drug Wegovy for $249 per month.
The program aims to make obesity and diabetes treatments more accessible, addressing supply shortages of popular medications like Wegovy and Ozempic by providing lower-cost compounded semaglutide, the active ingredient in these drugs.
Also Read: Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested.
The company's platform allows patients to book and pay for appointments directly with doctors and specialists, bypassing insurers. Sesame already offers branded weight loss and diabetes treatments, including through a partnership with Costco Wholesale Corporation (NASDAQ:COST).
However, the introduction of compounded medications provides a more affordable alternative, given that brand-name drugs like Wegovy and Ozempic can cost around $1,000 per month before insurance coverage.
Supply shortages have become a critical challenge for Novo Nordisk and Eli Lilly And Co (NYSE:LLY), leading to the offering of compounded versions when brand-name supplies dwindle.
Compounded medications, tailored to individual patient needs, are governed under specific FDA regulations.
The CNBC report added that Sesame has partnered with a 503B compounding pharmacy that produces prefilled, single-use syringes, a move designed to reduce risks associated with improper dosing.
Michael Botta, president and co-founder of Sesame, told CNBC in an interview that Sesame initially hesitated to offer compounded medications due to concerns about quality, but after inspecting the processes of its pharmacy partner, the company became confident in the safety and effectiveness of the treatments.
Price Action: NVO stock is down 1.26% at $134.10 at last check Wednesday.
- Eli Lilly's Famed Obesity/Diabetes Treatment Tirzepatide Shows Potential To Cut Risk Of Developing Diabetes, Sustained Weight Loss Over 3 Years.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo:Tobias Arhelger/Shutterstock.com
医疗保健平台Sesame宣布推出新的减肥计划，提供诺和诺德（纽交所代码：NVO）的畅销药物Wegovy的复方版本，价格为每月249美元。
该计划旨在使肥胖症和糖尿病的治疗更加可及，解决了Wegovy和Ozempic等热门药物供应短缺的问题，通过提供价格较低的复方塞鲁肽来解决。塞鲁肽是这些药物的活性成分。
另请参阅：Ozempic和Wegovy在观察性研究中与自杀念头增加有关，但结果存在争议。
该公司的平台允许患者直接与医生和专家预约和付费，绕过保险公司。Sesame已经提供品牌减肥和糖尿病治疗，包括与好市多（纳斯达克代码：COST）合作。
然而，复方药物的推出提供了更经济实惠的选择，因为像Wegovy和Ozempic这样的品牌药物在保险覆盖之前每月可能需要花费约1000美元。
供应短缺已成为诺和诺德和礼来（纽交所代码：LLY）面临的重要挑战，因此在品牌药物供应不足时提供复方版本。
根据FDA的具体规定，复方药物是根据每个患者的需求定制的。
CNBC的报道补充说，Sesame已与一家生产预注射、一次性使用注射器的5030亿复方药房合作，旨在降低剂量错误的风险。
Sesame的总裁兼联合创始人Michael Botta在接受CNBC采访时表示，由于对质量的担忧，Sesame最初对提供复合药物持犹豫态度，但在检查了其药房合作伙伴的流程后，公司对这种治疗的安全性和有效性充满信心。
股票价格走势：NVO股票最后一次查询时，下跌1.26%，至134.10美元。
- 艾默生（Eli Lilly）的著名肥胖/糖尿病治疗Tirzepatide显示，在3年内降低患糖尿病的风险，实现持续减重。
免责声明：本内容部分使用人工智能工具生成，并经Benzinga编辑审核发布。
图片：Tobias Arhelger/Shutterstock.com
